FDA Brief

Warning letters Devices

FDA warning letter to

Qianjiang Kingphar Medical Material Co Ltd.

High riskIssued Oct 3, 2025Posted Oct 28, 2025Center for Devices and Radiological Health

FDA warned Chinese device maker Qianjiang Kingphar that dirty cleanrooms and weak environmental controls make its masks, dressings, wraps and drapes adulterated.

What happened

FDA inspected the Qianjiang, China plant from June 30 to July 3, 2025. Investigators saw dirt and filth on cleanroom floors and walls, peeling floor molding, and cleaning logs that recorded surfaces as clean when they were not. FDA also found the firm had no alert or action limits for airborne and microbial particle counts in its ISO 8 cleanrooms and no clear rules for handling out-of-limit results.

What FDA found

  1. The firm did not keep up procedures to stop equipment or product from being contaminated, and its cleanroom cleaning records were inaccurate.

    21 CFR 820.70(e)
  2. The firm did not set alert and action limits for particle and microbial counts in its cleanrooms and had no clear steps for what to do when limits are exceeded.

    21 CFR 820.70(c)

What FDA wants

FDA wants a written reply within 15 business days describing the specific fixes and corrective actions, including a timetable and steps to prevent repeat problems, plus English translations of any documents not in English.

Who should pay attention

  • brands and distributors that buy finished devices from this contract manufacturer
  • sterile-barrier packaging and wound care companies sourcing from China
  • quality teams running ISO 8 cleanrooms for medical devices

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  2. Jabil Inc.

    FDA warned Jabil Inc. after an inspection found inadequate investigations of mold and sterility failures at its sterile injectable contract manufacturer.

    High risk
  3. Eugia Pharma Specialities Limited

    FDA warned Eugia Pharma Specialities that flawed aseptic line design and poor aseptic practices at its Kolthur Village plant risk contaminating sterile injectables.

    High risk
  4. Fareva Amboise

    FDA warned Fareva Amboise in France about sterile drug manufacturing failures, including aseptic practice and data integrity problems.

    High risk